actin related protein 3BGenealiases: ARP11 · ARP3BETA
Q-omics provides the consensus-scored ACTR3B profile across patient tissues and cancer cell-line models. ACTR3B expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, ACTR3B is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, ACTR3B RNA expression shows 20,040 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, COAD, and ACC as cancer lineages where ACTR3B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ACTR3B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ACTR3B survival associations across molecular data types. ACTR3B RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ACTR3B RNA expression–survival associations across cancer types. High ACTR3B expression shows unfavorable associations in LIHC, ACC, UVM and KICH, but favorable associations in STAD and LUAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for ACTR3B RNA expression.
This table summarizes ACTR3B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in LUAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ACTR3B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ACTR3B shows lower tumor expression in KIRC and higher tumor expression in COAD, LUAD, STAD, LIHC and BLCA. The COAD box plot shows higher ACTR3B RNA expression in tumor versus normal tissue (log2 FC = +1.199, t-test p < 0.001).
This table shows molecular features associated with ACTR3B in patient tissues and cancer cell lines. In patient samples, ACTR3B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ACTR3B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BONE.
